文献速递头颈部肿瘤放疗放疗物理与技术

单中心前瞻性试验:连续FDG-PET引导适应性放疗用于头颈癌的可行性

Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-04-30

该单中心前瞻性试验纳入20例下咽、喉或口咽T2-4鳞癌患者,在放疗第2、4周末行FDG-PET/CT重新勾画与计划,对原发肿瘤代谢活跃区按部分代谢缓解追加4 Gy(基础70 Gy)。85%的适应性调整成功完成,无≥4级急性毒性,达到可行性标准。

要点

  • 连续FDG-PET/CT引导适应性追加剂量在头颈癌中可行,85%调整成功完成。
  • 12例因第2、4周部分代谢缓解接受78 Gy,7例接受74 Gy。
  • 无≥4级急性毒性,3级吞咽困难(需管饲)从治疗中40%降至治疗后12周20%。

核心结论

  • 连续FDG-PET/CT用于剂量递增和患者选择在头颈癌中是可行的。

研究设计与样本

  • 单中心前瞻性试验(NCT03376386),共20例接受根治性放疗(±全身治疗)的T2-4下咽、喉或口咽鳞癌患者。

主要发现

  • 1例第2周完全代谢缓解者接受70 Gy,12例第2、4周部分代谢缓解者接受78 Gy,7例接受74 Gy。
  • 4次FDG-PET/CT因未禁食(n=2)或患者要求(n=2)而错过,另有2个适应性计划因后勤问题未成功完成。
  • 85%的适应性调整正确完成,无患者发生≥4级毒性。
  • 治疗中40%出现3级吞咽困难(需管饲),治疗后12周降至20%。

关键数值与推荐

  • 原发肿瘤代谢活跃区在70 Gy基础上按部分代谢缓解每次追加4 Gy。
  • 可行性标准为≥80%适应性调整成功且无CTCAE≥4级急性毒性。

临床怎么用

  • 可考虑在放疗第2、4周行FDG-PET/CT重新勾画与计划,对部分代谢缓解者追加剂量。
  • 需注意禁食等流程管理以减少FDG-PET/CT错过和计划失败。

局限性

  • 单中心、样本量小(20例),未设对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We investigated in a single-center prospective trial (NCT03376386) the use of serial fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) to determine the boost dose and to guide boost segmentation in head and neck cancer. METHODS AND MATERIALS: Patients were eligible when treated with curative radiation therapy with or without systemic treatment for T2-4 squamous cell carcinoma of the hypopharynx, larynx, or oropharynx (20 patients in total). FDG-PET/CT scans were made at baseline and for redelineation and replanning at the end of weeks 2 and 4 of radiation therapy. The metabolically active part of the primary tumor received a 4 Gy boost on top of the 70 Gy baseline dose per partial metabolic response. The study would be considered feasible when ≥80% of adaptations were successful and no Common Terminology Criteria for Adverse Events grade ≥4 acute toxicity occurred. RESULTS: One patient received 70 Gy after complete metabolic response in week 2, and 12 patients received 78 Gy because of partial metabolic response at weeks 2 and 4. Seven patients received 74 Gy, either because of complete metabolic response at week 4 (n = 3) or a missed FDG-PET/CT (n = 4). The patients missed their FDG-PET/CT scans because they did not fast (n = 2) or at patients' request (n = 2). In addition to the 4 missed FDG-PET/CT scans, 2 adaptive plans could not be finished successfully owing to logistical problems. In total, 85% of adaptations were completed correctly. No patient experienced grade ≥4 toxicity, and 40% had grade 3 dysphagia (tube feeding) during treatment. This decreased at 12 weeks posttreatment to 20%. CONCLUSIONS: This prospective trial demonstrates the feasibility of serial FDG-PET/CT scans for dose escalation and patient selection.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gouw ZAR, La Fontaine MD, Vogel WV, et al. Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32361007. doi:10.1016/j.ijrobp.2020.04.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。